

Special Issue

Periodontal Bacteria and Periodontitis: Infections and Therapy

Message from the Guest Editor

Periodontitis is a progressive and destructive inflammatory disease that affects the teeth supporting tissues. Its complex ethiology takes into account the interaction between subgingival microflora, the body's immune response and environmental factors. Bacterial biofilm is considered the main etiological factor causing gingivitis and leading to the destruction of periodontal tissues. Periopathogens in the subgingival area triggers defense mechanisms associated with the production of inflammatory factors and increased amounts of gingival crevicular fluid. As a result of inflammation and increased expression of proinflammatory cytokines, periodontal tissues are destroyed. Due to the infectious nature of the disease, treatment of periodontitis focuses largely on eliminating bacteria from the oral cavity. This Special Issue seeks manuscripts dealing with periodontal disease, especially those dealing with its infection nature and therapy, antibiofilm strategies and means that can improve the therapeutic effect. Both original research and review articles are welcome.

Guest Editor

Dr. Anna Skurska

Department of Integrated Dentistry, Medical University of Białystok, 15-276 Białystok, Poland

Deadline for manuscript submissions

31 March 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/228047

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)